Replies to post #252110 on Biotech Values

[DewDiligence]

PFE’s Abryvso wins 5M-dose UK contract:

https://www.fiercepharma.com/pharma/rallying-rsv-vaccine-race-pfizer-gains-contract-win-over-gsk-uk

[DewDiligence]

GSK—FDA expands Arvexy label to age 18-49 for individuals with at least one risk factor:

https://www.businesswire.com/news/home/20260313340226/en/GSKs-RSV-Vaccine-AREXVY-Approved-in-US-for-Expanded-Age-Indication-in-Adults-Aged-1849-Years-at-Increased-Risk

Until now, Arvexy was FDA-approved for adults age 50+ (#msg-174567339). The expanded label puts GSK on an equal footing with the other RSV vaccines in the US market.